NecroX-7 是一种有效的自由基清除剂，是一种HMGB1(高迁移率族蛋白 1) 抑制剂。NecroX-7 可以作为对乙酰氨基酚毒性的解毒剂。NecroX-7 通过抑制缺血/再灌注损伤中 HMGB1 的释放发挥保护作用。NecroX-7 抑制 HMGB1 诱导的TNF和IL-6的释放，以及TLR-4和晚期糖基化终产物受体的表达。NecroX-7 可用于移植物抗宿主病 (GVHD) 研究。
| 生物活性 | NecroX-7 is a potent free radical scavenger and aHMGB1(high-mobility group box 1) inhibitor. NecroX-7 can be used as an antidote to acetaminophen toxicity. NecroX-7 exerts a protective effect by preventing the release of HMGB1 in ischemia/reperfusion injury. NecroX-7 inhibits the HMGB1-induced release ofTNFandIL-6, as well as the expression ofTLR-4and receptor for advanced glycation end products. NecroX-7 can be used graft-versus-host disease (GVHD) research[1]. |
| IC50& Target | |
体外研究
(In Vitro) | NecroX-7 (0-40 μM, 3-4 d) suppresses activated or proliferating T cells without causing apoptosis[1].
NecroX-7 (0-40 μM) markedly reduces HMGB1 levels in a dose-dependent manner[1].
NecroX-7 inhibits formation of mitochondria-specific ROS/reactive nitrogen species in H9C2 cells and hepatocytes after induction by tert-butyl hydroperoxide or doxorubicin[1].
NecroX-7 increased regulatory T cell numbers, which may be associated with regulation of differentiation signals independent of HMGB1[1].
Cell Proliferation Assay[1] | Cell Line: | CD4 T cells | | Concentration: | 0, 0.625, 1.25, 2.5, 5, 10, 20, and 40 μM | | Incubation Time: | 3-4 d | | Result: | Showed a marked reduction in splenocyte proliferation, in a dose-dependent manner. Modulated alloreactive T cell responses. |
|
体内研究
(In Vivo) | NecroX-7 (0-0.3 mg/kg, IV, once injection at 2-d intervals, for 2 weeks) significantly attenuates GVHD-related mortality and inhibits severe tissue damage[1].
NecroX-7 protects mice against lethal GVHD by reciprocal regulation of regulatory T/Th1 cells, attenuating systemic HMGB1 accumulation and inhibiting HMGB1-mediated inflammatory response[1].
| Animal Model: | Female BALB/c and C57BL/6 mice (Eight-week-old, with GVHD)[1] | | Dosage: | 0.03, 0.1, and 0.3 mg/kg | | Administration: | IV, once injection at 2-d intervals, for 2 weeks | | Result: | Observed statistically significant prolonged survival at doses ≥0.1 mg/kg: 30–60% of mice in these treatment groups survived for >50 d. Significantly improved clinical signs and prolonged survival, and the mice showed a reduction in clinical manifestations of acute GVHD, including weight loss, hunched posture, diarrhea, and ruffled fur. |
|
| 分子量 | |
| Formula | |
| CAS 号 | |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
m.cnreagent.com